Alpine Immune Sciences, Inc. (ALPN) financial statements (2020 and earlier)

Company profile

Business Address 201 ELLIOTT AVE. WEST, SUITE 230
SEATTLE, WA 98119
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4752816187
Cash and cash equivalents171182425
Short-term investments2942733762
Restricted cash and investments0    
Receivables000  
Prepaid expense100  
Deferred costs 0   
Other undisclosed current assets50110
Total current assets:5254836288
Noncurrent Assets
Operating lease, right-of-use asset11
Property, plant and equipment11100
Intangible assets, net (including goodwill)  1  
Intangible assets, net (excluding goodwill)  1  
Restricted cash and investments000  
Other undisclosed noncurrent assets   00
Total noncurrent assets:121300
TOTAL ASSETS:6555856288
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities126143
Accounts payable62021
Accrued liabilities64000
Employee-related liabilities   22
Deferred revenue2
Debt 21  
Deferred rent credit 0
Deferred revenue and credits0  
Other undisclosed current liabilities   32
Total current liabilities:148264
Noncurrent Liabilities
Long-term debt and lease obligation1624  
Long-term debt, excluding current maturities524  
Operating lease, liability11
Liabilities, other than long-term debt  0  
Deferred revenue and credits0  
Deferred tax liabilities, net 0  
Total noncurrent liabilities:1624  
Total liabilities:3010664
Stockholders' equity
Stockholders' equity attributable to parent, including:3545795583
Common stock   00
Additional paid in capital1179188236232
Accumulated other comprehensive income (loss)0(0)(0)(0)0
Accumulated deficit(82)(46)(9)(180)(149)
Other undisclosed stockholders' equity attributable to parent000  
Total stockholders' equity:3545795583
TOTAL LIABILITIES AND EQUITY:6555856288

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenue, net2  
Gross profit:112  
Operating expenses(49)(39)(17)(32)(23)
Operating loss:(48)(38)(15)(32)(23)
Nonoperating income  7 0
Investment income, nonoperating  7  
Interest and debt expense(0)(0)(0)  
Loss from continuing operations before equity method investments, income taxes:(48)(38)(9)(32)(23)
Other undisclosed income from continuing operations before income taxes111  
Loss from continuing operations before income taxes:(47)(37)(8)(32)(23)
Income tax benefit000  
Net loss:(47)(36)(8)(32)(23)
Other undisclosed net income attributable to parent   0 
Net loss available to common stockholders, diluted:(47)(36)(8)(31)(23)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(47)(36)(8)(32)(23)
Comprehensive loss:(47)(36)(8)(32)(23)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent00(0)00
Comprehensive loss, net of tax, attributable to parent:(47)(36)(8)(31)(23)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: